Australia is currently observing the arrival of retatrutide, a novel dual GIP and GLP-1 receptor medication , representing a significant advance in obesity treatment . Early clinical trials have demonstrated https://deniskjxv951383.fitnell.com/84979136/emerging-medication-in-australia-a-potential-solution-for-obesity-management